Our Oligo Modifications service supports biotech companies, pharmaceutical discovery teams, CROs, academic laboratories, and assay developers that need custom DNA, RNA, or hybrid oligonucleotides with project-specific chemical functionality. We help clients move beyond standard sequences by planning and producing modified oligos for detection, capture, conjugation, nuclease-resistance optimization, ligation workflows, structural tuning, and advanced nucleic acid research. Whether the goal is a labeled probe, a conjugation-ready handle, a backbone-adjusted construct, or a sequence carrying multiple coordinated modifications, we align chemistry choices with the downstream experiment rather than treating modification as a simple catalog add-on.
Our platform combines sequence review, modification route assessment, custom synthesis, purification planning, analytical characterization, and application-focused support to reduce redesign cycles and outsourcing fragmentation. We can coordinate modification strategies across oligo labeling modifications, oligo backbone modification, oligo base modification, oligo spacer modification, oligo phosphorylation modification, 2'-modifications, and broader oligonucleotide conjugation services so clients receive a more workable construct, a clearer release package, and a service path matched to real development constraints.
Weak Signal or Incomplete Readout: A modified oligo must fit the actual detection format, not just carry a label. We help teams choose reporter chemistry, quencher pairing, modification position, and spacer strategy so signal generation, spectral compatibility, and background control are aligned with the instrument and assay workflow.
Poor Stability or Undesired Enzymatic Behavior: Many research programs need better resistance to nucleases, blocked extension, or ligation-ready termini. We support backbone, sugar, and terminal-phosphate planning so modified oligos are better matched to cell-free assays, nuclease-exposed workflows, and downstream enzymatic steps.
Steric Hindrance in Capture or Surface Assays: Biotinylated, immobilized, and surface-bound oligos often fail because the functional group is too close to the hybridizing region. Our team reviews linker length, terminal versus internal placement, and spacer selection to improve accessibility in pull-down, enrichment, chip, bead, and plate-based systems.
Conjugation Bottlenecks After Synthesis: Amino-, thiol-, and click-ready oligos are only useful when the reactive handle remains accessible and compatible with the planned coupling route. We design modification geometry around downstream dye, peptide, lipid, polymer, protein, or nanoparticle conjugation needs to reduce expensive reformulation or resynthesis.
Low Recovery in Multi-Modified Constructs: Hydrophobic dyes, multiple labels, or dense modification patterns can affect coupling efficiency, purification burden, and final usability. We assess sequence length, modification density, chemistry compatibility, and purification route early so feasibility, QC expectations, and delivery format are realistic from the start.
Our oligo modification services are structured for teams that need technically coordinated support across modification design, synthesis execution, purification, and release testing. We work with single-site and multi-site modification programs, including standard research reagents, multiplex probes, conjugation intermediates, and sequence-specific constructs that require both chemical precision and practical workflow awareness.
Rather than offering a flat list of available chemistries, we review sequence context, intended placement, modification compatibility, purification difficulty, and end-use requirements before recommending a route. This helps procurement and scientific teams make better decisions on feasibility, construct architecture, and the balance between functionality and manufacturability.
| Classification | Modifications | Purification |
| Fluorescent labeling | 6-FAM (NHS ester) | HPLC/PAGE |
| Cy3 | ||
| Cy3.5 | ||
| TAMRA | ||
| JOE (NHS ester) | ||
| Cy5 | ||
| TAMRA (NHS ester) | ||
| MAX (NHS ester) | ||
| TET | ||
| Cy5.5 | ||
| ROX (NHS ester) | ||
| TYE 563 | ||
| HEX | ||
| TEX 615 | ||
| TYE 665 | ||
| TYE 705 | ||
| SUN | ||
| Classification | Modifications | Purification |
| Backbone modification | Bridged Nucleic Acids (BNA) | HPLC/PAGE |
| 2' Fluoro RNA | ||
| 2' O-Methyl RNA (2'OMe) | ||
| 2'-F-ANA | ||
| L-DNA | ||
| L-RNA | ||
| Phosphorothioate DNA | ||
| Phosphorothioate RNA | ||
| Phosphonoacetate (PACE) | ||
| Methylphosphonate linkages | ||
| ZNA Spermine |
| Classification | Modifications | Purification |
| Spacer | SpC3 | HPLC/PAGE |
| SpC6 | ||
| SpC12 | ||
| Sp9 | ||
| Sp18 | ||
| dSp | ||
| rSp | ||
| PLC |
| Classification | Modifications | Purification |
| Phosphorylation | 3-Phos | HPLC/PAGE |
| 5'-P | ||
| Tri-Phos |
This table helps project teams compare the main oligo modification families by purpose, preferred placement logic, and the development questions that usually determine whether a design is straightforward, customization-heavy, or likely to require additional review.
| Modification Category | Primary Purpose | Common Placement | Key Decision Factors | Typical Research Workflows |
| Fluorescent Labels | Generate direct optical readout for detection, tracking, or imaging | 5', 3', or internal | Dye compatibility, spectral channel fit, self-quenching risk, purification burden | Hybridization assays, qPCR-adjacent probes, localization studies, multiplex detection |
| Reporter-Quencher Pairs | Control background and create signal-on or signal-change probe behavior | Dual terminal or terminal plus internal | Pair selection, probe length, Tm balance, structural folding behavior | Hydrolysis probes, molecular beacons, FRET assays, target discrimination systems |
| Affinity Tags | Enable capture, enrichment, pull-down, purification, or surface immobilization | Mostly terminal, sometimes internal | Tag exposure, spacer need, surface chemistry, steric accessibility | Pull-down assays, bead capture, chip assays, enrichment and recovery workflows |
| Reactive Handles | Create a defined chemical handle for post-synthesis conjugation | 5', 3', or internal | Coupling route, linker geometry, handle protection, payload size | Dye coupling, peptide attachment, polymer linking, nanoparticle assembly |
| Backbone Modifications | Improve stability or alter physicochemical behavior of the oligo scaffold | Distributed through the sequence or localized at selected positions | Nuclease exposure, affinity tradeoff, synthesis complexity, assay compatibility | Blocking oligos, stabilized guides, discovery-stage antisense formats, challenging matrices |
| Base and Sugar Modifications | Adjust affinity, selectivity, stability, or sequence-function behavior | Position-specific internal substitution | Tm impact, mismatch behavior, enzymatic tolerance, structural constraints | High-specificity probes, siRNA design support, structure-function studies, guide tuning |
| Spacers | Add distance, flexibility, or non-hybridizing interruption | Terminal or internal | Required separation, linker length, surface presentation, folding effects | Surface capture, beacon design, immobilized probes, conjugate presentation |
| Phosphate Modifications | Enable ligation, block extension, or create terminal functionality | Usually 5' or 3' | Enzymatic workflow, end blocking needs, construct orientation | Ligation studies, adapter construction, blocked primers, defined-end oligos |
| Lipid or Ligand Labels | Add targeting, membrane interaction, or delivery-oriented functionality | Usually terminal | Hydrophobic load, solubility, aggregation risk, release expectations | Uptake studies, formulation screening, delivery feasibility, targeted research reagents |
Successful oligo modification projects depend on more than selecting a chemical label. The matrix below outlines the review areas that most often determine whether a modified oligo is easy to execute, difficult to purify, or likely to need redesign before it performs reliably in the intended workflow.
| Planning Category | Why It Matters | What We Review | Customer Output | Most Critical Stage |
| Sequence Context Review | Modification performance depends on neighboring bases, length, and secondary-structure risk | GC pattern, repetitive regions, terminal composition, self-complementarity | Feasibility comments and sequence-risk notes | Project intake |
| Placement Strategy | 5', 3', and internal positions can change accessibility and functional outcome | Terminal versus internal logic, spacing from hybridizing region, positional burden | Recommended modification map | Design stage |
| Chemistry Compatibility | Not all modification combinations behave well under the same synthesis and deprotection conditions | Reagent compatibility, protection strategy, route sequencing, multi-mod feasibility | Practical synthesis route and risk flags | Design stage |
| Purification Burden | Hydrophobic labels and dense modification patterns can reduce recovery and complicate cleanup | Label class, construct heterogeneity, expected byproducts, target purity needs | Purification recommendation and realistic release expectations | Pre-synthesis |
| Analytical Verification | Modified constructs need identity and fit-for-use confirmation before downstream testing | Mass confirmation, purity profile, modification incorporation, appearance and handling notes | QC and analytical summary package | Post-synthesis |
| Downstream Conjugation Fit | A reactive handle is only valuable when it remains usable in the customer's coupling workflow | Handle accessibility, linker choice, payload compatibility, storage and transfer conditions | Conjugation-oriented handling guidance | Post-synthesis / pre-transfer |
| Application Translation | Modified oligos can fail if chemistry, format, and workflow expectations are not aligned early | Assay format, detection mode, capture geometry, matrix exposure, control strategy | Project-aligned recommendation for construct use | Final review |
| Scale-Up Readiness | A design that works at exploratory scale may not translate cleanly into larger production lots | Modification density, route reproducibility, purification load, batch-consistency risks | Scale guidance and next-step planning | Later development |
Our workflow is built for research and development projects that need more than a simple sequence quote. Each stage is designed to translate a desired modification concept into a workable oligo construct with clearer feasibility, more predictable synthesis, and fit-for-purpose analytical release.
We begin by reviewing the target sequence, oligo type, intended application, modification goal, preferred scale, and any existing assay or conjugation constraints. This helps define whether the project is best approached as a labeling, backbone, base/sugar, spacer, phosphorylation, or multi-modification program.
Our team evaluates sequence context, modification placement, chemistry compatibility, and likely purification burden before finalizing the construct map. Where relevant, we also review whether internal links to related options such as conjugation, spacer insertion, or 2'-modification strategies would improve the project route.
Once the design is defined, we establish the synthesis plan, select suitable modification reagents, and determine the analytical package needed for release. At this stage we align the expected purity target, handling form, and any project-specific testing with the complexity of the requested construct.
The modified oligo is synthesized using a route matched to its chemistry profile, followed by deprotection and purification appropriate for sequence length, label class, and modification density. For demanding constructs, purification is planned as a functional step in project success rather than a routine afterthought.
We verify the construct through the agreed analytical workflow, such as identity confirmation and purity assessment, and review whether the released material is suitable for the intended experiment. For conjugation-ready or multi-modified oligos, particular attention is given to integrity, usability, and handling considerations.
Final materials are delivered with structured documentation to support internal technical review, method transfer, or next-round design refinement. If follow-up work is needed, we can help extend the project into related services such as fluorescent labeling, backbone optimization, spacer redesign, or oligonucleotide conjugation.
Oligo modification projects often fail when chemistry selection, sequence design, and downstream use are handled in isolation. Our service model is built to connect those decisions early, so clients receive not just a modified oligo, but a construct that is more likely to be usable in real research workflows.
Modified oligonucleotides are used when a standard sequence is not enough for the intended research workflow. Our service supports application-driven designs where detection, stability, capture, conjugation, or structure-sensitive performance must be built into the oligo from the start.
Whether you need a fluorescent probe, a capture-ready biotin oligo, a conjugation handle, a stabilized backbone format, or a multi-modified custom construct, our team can help translate your sequence requirements into a workable development plan. We support research organizations that need clear technical review, flexible modification strategies, reliable analytical release, and a smoother path from inquiry to experimental use. From exploratory constructs to more demanding custom modification programs, our service platform is built to help you choose, build, and evaluate modified oligos with fewer redesign cycles and better alignment to your downstream workflow. Contact us to discuss your oligo modification requirements.
Spacer modifications involve adding spacer molecules to an oligonucleotide sequence to control the length and flexibility of the spacer arm. These modifications help improve hybridization efficiency and prevent enzymatic degradation.
Spacer C18 is a long hexaethylene glycol chain that can be added at the 5' or 3' end of an oligonucleotide. It is commonly used to form hairpin loops, create bold folds, and immobilize probes on solid phases.
Spacer C3 is a short 3-carbon chain used to add flexibility at the ends or within the oligonucleotide. It is often used to link fluorophores or other molecules to the oligo for enhanced functionality.
Spacer C9 consists of a triethylene glycol chain and is more hydrophilic than C3, which enhances its ability to form non-nucleotide bridges. It is commonly used in hairpin loop formation and immobilizing probes in solid-phase applications.
dSpacer is an abasic furan derivative that creates a stable abasic site in DNA oligonucleotides. It is used in experiments involving base excision repair or UV-induced depurination events.
A photocleavable spacer (PLC) is designed to be cleaved under UV light, enabling controlled release of the oligonucleotide sequence. This feature is useful for applications that require temporary linkage of oligonucleotides.
Loading ......
